PubMed

Beneficial effects of insulin on glycemic control and beta-cell function in newly diagnosed type 2 diabetes with severe hyperglycemia after short-term intensive insulin therapy.

Chen HS, Wu TE, Jap TS, Hsiao LC, Lee SH, Lin HD.

Diabetes Care. 2008 Oct;31(10):1927-32. Epub 2008 Jun 12.PMID: 18556343 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.

Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Liu J, Li M, Fu Z, Cheng H.

Lancet. 2008 May 24;371(9626):1753-60.PMID: 18502299 [PubMed - indexed for MEDLINE]Related articles

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.

Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J.

Diabetes Care. 2004 Nov;27(11):2597-602.PMID: 15504992 [PubMed - indexed for MEDLINE]Related articlesFree article

Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.

Ilkova H, Glaser B, Tunçkale A, Bagriaçik N, Cerasi E.

Diabetes Care. 1997 Sep;20(9):1353-6.PMID: 9283777 [PubMed - indexed for MEDLINE]Related articles

Short-term intensive insulin therapy in newly diagnosed type 2 diabetes.

Ryan EA, Imes S, Wallace C.

Diabetes Care. 2004 May;27(5):1028-32.PMID: 15111515 [PubMed - indexed for MEDLINE]Related articlesFree article

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial.

Bunck MC, Diamant M, Cornér A, Eliasson B, Malloy JL, Shaginian RM, Deng W, Kendall DM, Taskinen MR, Smith U, Yki-Järvinen H, Heine RJ.

Diabetes Care. 2009 May;32(5):762-8. Epub 2009 Feb 5.PMID: 19196887 [PubMed - indexed for MEDLINE]Related articlesFree article

[Influencing factors for the curative effects of short-term continuous subcutaneous insulin infusion on newly diagnosed type 2 diabetes]

Li YB, Zhu HL, Yao B, Huang ZM, Ou XZ, Xiao YB, Weng JP.

Zhonghua Yi Xue Za Zhi. 2005 Mar 9;85(9):602-5. Chinese. PMID: 15949356 [PubMed - indexed for MEDLINE]Related articles

Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia.

Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE.

J Clin Endocrinol Metab. 2008 Jan;93(1):103-9. Epub 2007 Oct 9.PMID: 17925336 [PubMed - indexed for MEDLINE]Related articlesFree article

United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. United Kingdom Prospective Diabetes Study Group.

[No authors listed]

Ann Intern Med. 1998 Feb 1;128(3):165-75.PMID: 9454524 [PubMed - indexed for MEDLINE]Related articlesFree article

Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM). Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes.

Abraira C, Colwell JA, Nuttall FQ, Sawin CT, Nagel NJ, Comstock JP, Emanuele NV, Levin SR, Henderson W, Lee HS.

Diabetes Care. 1995 Aug;18(8):1113-23.PMID: 7587846 [PubMed - indexed for MEDLINE]Related articles

Thiazolidinediones increase hepatic insulin extraction in African Americans with impaired glucose tolerance and type 2 diabetes mellitus. A pilot study of rosiglitazone.

Osei K, Gaillard T, Schuster D.

Metabolism. 2007 Jan;56(1):24-9.PMID: 17161222 [PubMed - indexed for MEDLINE]Related articles

Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents.

Kohnert KD, Augstein P, Zander E, Heinke P, Peterson K, Freyse EJ, Hovorka R, Salzsieder E.

Diabetes Care. 2009 Jun;32(6):1058-62. Epub 2009 Feb 24.PMID: 19244086 [PubMed - indexed for MEDLINE]Related articlesFree article

Evaluations of retinopathy in the VA Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM). A feasibility study.

Emanuele N, Klein R, Abraira C, Colwell J, Comstock J, Henderson WG, Levin S, Nuttall F, Sawin C, Silbert C, Lee HS, Johnson-Nagel N.

Diabetes Care. 1996 Dec;19(12):1375-81.PMID: 8941467 [PubMed - indexed for MEDLINE]Related articles

Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.

Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.

Clin Ther. 2007 Nov;29(11):2374-84.PMID: 18158078 [PubMed - indexed for MEDLINE]Related articles

Near-normoglycaemic remission in African-Americans with Type 2 diabetes mellitus is associated with recovery of beta cell function.

McFarlane SI, Chaiken RL, Hirsch S, Harrington P, Lebovitz HE, Banerji MA.

Diabet Med. 2001 Jan;18(1):10-6.PMID: 11168335 [PubMed - indexed for MEDLINE]Related articles

The switch from sulfonylurea to preprandial short- acting insulin analog substitution has an immediate and comprehensive beta-cell protective effect in patients with type 2 diabetes mellitus.

Pfützner A, Lorra B, Abdollahnia MR, Kann PH, Mathieu D, Pehnert C, Oligschleger C, Kaiser M, Forst T.

Diabetes Technol Ther. 2006 Jun;8(3):375-84.PMID: 16800759 [PubMed - indexed for MEDLINE]Related articles

Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.

Vinik A.

Clin Ther. 2007 Jun;29(6 Pt 1):1236-53. Review.PMID: 18036387 [PubMed - indexed for MEDLINE]Related articles

The effects of metformin on glycemic control and serum lipids in insulin-treated NIDDM patients with suboptimal metabolic control.

Robinson AC, Burke J, Robinson S, Johnston DG, Elkeles RS.

Diabetes Care. 1998 May;21(5):701-5.PMID: 9589227 [PubMed - indexed for MEDLINE]Related articlesFree article

Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy.

Vinik A.

Clin Ther. 2007;29 Spec No:1236-53. Review.PMID: 18046925 [PubMed - indexed for MEDLINE]Related articles

U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group.

[No authors listed]

Diabetes. 1995 Nov;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45(11):1655. PMID: 7589820 [PubMed - indexed for MEDLINE]Related articles